Executive Summary
Shandong Weigao Group Medical Polymer reported QQ1 2025 revenue of 3,322,024,000 CNY, up 2.99% quarter-on-quarter and up 0.13% year-on-year. The company preserved a robust gross margin of 49.72% (Gross Profit 1,651,754,000 CNY) and delivered an EBITDA margin of approximately 24.66% (EBITDA 819,198,000 CNY), underscoring a solid cost structure and favorable product mix in a competitive Chinese market. Operating income stood at 587,872,500 CNY, yielding an operating margin of 17.70%, while net income reached 504,158,500 CNY with an implied net margin near 15.18% and basic EPS of 0.11 CNY for the quarter. These results reflect sustained profitability even as top-line growth remains modest on a year-over-year basis. A notable feature of QQ1 2025 is the discipline around R&D and SG&A expenditures: R&D was 157,766,000 CNY (about 4.75% of revenue) and Selling, General & Administrative expenses totaled 906,115,500 CNY, implying continued investment in product development and market reach while maintaining profit integrity.
Two important caveats frame the interpretation: first, the input data shows a minor discrepancy in reported year-over-year net income (the accompanying YoY narrative suggests a decline of ~8.96% while the quarterly figures imply a softer-to-stronger YoY trajectory depending on the period compared). Readers should align with the company’s official filings for a reconciled YoY view. Second, liquidity and balance-sheet metrics are not provided in the excerpt, so cash-flow health, leverage, and working capital dynamics require a dedicated data pull from the balance sheet and cash-flow statement. Still, QQ1 2025 demonstrates margin resilience and a stable earnings base in a domestic healthcare environment.
Key Performance Indicators
Key Insights
Revenue: 3,322,024,000 CNY; YoY: 0.13%; QoQ: 2.99%
Gross Profit: 1,651,754,000 CNY; Gross Margin: 49.72%
EBITDA: 819,198,000 CNY; EBITDA Margin: 24.66%
Operating Income: 587,872,500 CNY; Operating Margin: 17.70%
Net Income: 504,158,500 CNY; Net Margin: 15.18%
EPS: 0.11 CNY; EPS Diluted: 0.11 CNY
R&D Expenses: 157,766,000 CNY (~4.75% of revenue)
General & Administrative: 309,980,500 CNY
Selling & Marketing: 589,837,500 CNY
Selling, General & Administrative (SG&A): 906,115,500 ...
Financial Highlights
Revenue: 3,322,024,000 CNY; YoY: 0.13%; QoQ: 2.99%
Gross Profit: 1,651,754,000 CNY; Gross Margin: 49.72%
EBITDA: 819,198,000 CNY; EBITDA Margin: 24.66%
Operating Income: 587,872,500 CNY; Operating Margin: 17.70%
Net Income: 504,158,500 CNY; Net Margin: 15.18%
EPS: 0.11 CNY; EPS Diluted: 0.11 CNY
R&D Expenses: 157,766,000 CNY (~4.75% of revenue)
General & Administrative: 309,980,500 CNY
Selling & Marketing: 589,837,500 CNY
Selling, General & Administrative (SG&A): 906,115,500 CNY
Depreciation & Amortization: 231,325,500 CNY
Interest Expense: N/A in data
Total Cost & Expenses: 2,734,151,500 CNY
Weighted Average Shs Out: 4,583,300,757; Diluted: 4,543,114,720
Income Statement
| Metric |
Value |
YoY Change |
QoQ Change |
| Revenue |
3.32B |
0.13% |
2.99% |
| Gross Profit |
1.65B |
-2.16% |
4.57% |
| Operating Income |
587.87M |
-6.91% |
16.43% |
| Net Income |
504.16M |
-8.96% |
5.13% |
| EPS |
0.11 |
-8.33% |
10.00% |
Management Commentary
No QQ1 2025 earnings call highlights were provided in the input data. Management commentary from the transcript, if available, should be used to enrich the themes below (strategy, operations, market conditions), with quotes attributed to speakers and context for each quote.
Forward Guidance
No formal forward guidance was provided in the supplied QQ1 2025 data. In the absence of explicit targets, investors should monitor trajectory in revenue growth (especially QoQ momentum), sustained gross margin resilience, the pace of SG&A/R&D investment, and any planned capex or product launches that could alter the margin profile. Key factors to watch include regulatory changes affecting pricing or reimbursement, domestic demand growth for single-use devices, competitive dynamics, and any emerging international opportunities that could diversify the revenue base.